metastatic castration-resistant prostate cancer (mCRPC) research hub

A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors (EVICTION-2)

This study is testing new ways to treat advanced cancers like prostate, bowel, and skin cancer. It looks at the safety and how well a new drug, ICT01, works when given with another medicine, Proleukin, for people whose cancer has spread.